Genmab — August 2017
-
"Biopharma stages a strong recovery - EPR"
https://www.europeanpharmaceuticalreview.com/news/65096/biopharma-strong-recovery/ -
Nordea: Our updated forecasts reflect significant FX headwind from H2 2017 onwards, which also results in a ~5% cut to our DCF-based target price down to DKK 1,510 (1,577) per share. We maintain our Buy rating on Genmab but acknowledge that the stock may be range-bound until ESMO in September and 1L Darzalex data
-
Nordea: We have updated our model to reflect the recent significant depreciation of the USD, which takes down our estimates by 5-10% near-term and 3-5% longer-term.
-
Hvem kommer først med spørgsmål om dollaren i vores Q&A? Vi er bagud denne gang med spørgsmål.
-
Pipelinen i fokus i Genmab-regnskab
Salgstallene for kerneproduktet Darzalex er allerede meldt ud, og derfor vil fokus i det kommende halvårsregsnskab fra Genmab være på nyheder om biotekselskabets pipelineprojekter - og ikke så meget på regnskabstallene.
(medwatch.dk)
-
-
true bibob- however that is also not all their choice; firstly they are restricted from selling just before the accounts and secondly when they excercise warrants they will need to pay for them and thus sell some if they dont want to use (or dont have) their own funds
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind